Hung joins the board with more than 25 years of leadership and management experience in the life sciences industry.
Previously, he was the founder, president, and chief executive officer of Medivation from 2004 through 2016 when it was acquired by Pfizer for approximately USD 14bn.
Medivation developed Xtandi for the treatment of metastatic and non-metastatic prostate cancer from invention to FDA approval in seven years, one of the fastest development times in biopharmaceutical history.
In 2016, Xtandi had become the world's leading prostate cancer therapy, with nearly USD 2.5bn in annual revenue.
At Medivation, Hung built a pipeline of cancer therapies addressing significant unmet needs including a potentially best-in-class poly (ADP-ribose) polymerase inhibitor (talazoparib) which was recently approved for germline BRCA-mutated, HER2-negative, locally advanced and/or metastatic breast cancer.
From April 2017 to February 2018, Dr. Hung was chief executive officer and a director of Axovant Sciences, Inc.
He received an M.D. alpha omega alpha from the University of California, San Francisco, School of Medicine, and an A.B. summa cum laude in Biology from Harvard College.
Agilvax discovers and develops targeted antibody-based therapeutics for the treatment of various cancers.
The company's lead product, AX09, produces antibodies that specifically inhibit the function of xCT, a protein that is over expressed on many different tumor types including breast cancer, hepatocellular cancer, lung cancer, and pancreatic cancer.
Agilvax is developing AX09 initially for the treatment of metastatic triple negative breast cancer.
AbbVie's ELAHERE receives full US FDA approval
Johnson & Johnson's OPSYNVI receives US FDA approval
Outlook Therapeutics receives positive CHMP opinion for ONS-5010 in wet AMD treatment
Human Immunology Biosciences receives ODD from FDA for felzartamab
Eton Pharmaceuticals acquires PKU GOLIKE, expanding rare disease portfolio
Vertex receives FDA clearance for VX-407 Investigational New Drug Application for ADPKD
Phanes Therapeutics receives FDA Fast Track designation for PT886
Bio-Thera Solutions signs new licensing agreement with SteinCares
FDA accepts resubmission of Citius Pharmaceuticals, Inc's BLA for LYMPHIR
GSK Plc reports positive Phase III Jemperli data for endometrial cancer
ImmVira receives FDA Fast Track designation for MVR-T3011 IT